Characteristics before study transfusions of women with evaluable posttransfusion donor cell survival data
| . | LR arm (T1) . | NLR arm (T1) . | LR arm (T2) . | NLR arm (T2) . |
|---|---|---|---|---|
| Transfused female subjects | 55 | 55 | 24 | 29 |
| Female subjects transfused with ≥ 1 U male donor cells and evaluable data | 42 | 38 | 21 | 26 |
| Days between start of T1 and T2 transfusions* | NA | NA | 54 (27, 144) | 68 (16, 273) |
| Subject age (y)* | 35 (28, 47) | 38 (24, 48) | 35 (27, 44) | 37 (28, 48) |
| Race/ethnicity | ||||
| White (%) | 13 (31) | 16 (42) | 8 (38) | 9 (35) |
| Black (%) | 20 (48) | 17 (45) | 9 (43) | 14 (54) |
| Hispanic (%) | 9 (21) | 2 (5) | 4 (19) | 2 (8) |
| Other (%) | 0 | 3 (8) | 0 | 1 (4) |
| Route of HIV infection | ||||
| Intravenous drug use (%) | 12 (29) | 17 (45) | 8 (38) | 9 (35) |
| Heterosexual contact (%) | 28 (67) | 18 (47) | 12 (57) | 14 (54) |
| Other/unknown (%) | 2 (5) | 3 (8) | 1 (5) | 3 (11) |
| Previous HAART (%)† | 11 (26) | 7 (18) | 5 (24) | 8 (31) |
| Log10 HIV RNA* | 4.7 (2.6, 5.8) | 4.9 (2.7, 5.9) | 5.0 (3.8, 5.9) | 4.7 (2.7, 5.8) |
| CD4 cell count per μL* | 19 (2, 156) | 12 (2, 357) | 14 (2, 84) | 6 (1, 303) |
| . | LR arm (T1) . | NLR arm (T1) . | LR arm (T2) . | NLR arm (T2) . |
|---|---|---|---|---|
| Transfused female subjects | 55 | 55 | 24 | 29 |
| Female subjects transfused with ≥ 1 U male donor cells and evaluable data | 42 | 38 | 21 | 26 |
| Days between start of T1 and T2 transfusions* | NA | NA | 54 (27, 144) | 68 (16, 273) |
| Subject age (y)* | 35 (28, 47) | 38 (24, 48) | 35 (27, 44) | 37 (28, 48) |
| Race/ethnicity | ||||
| White (%) | 13 (31) | 16 (42) | 8 (38) | 9 (35) |
| Black (%) | 20 (48) | 17 (45) | 9 (43) | 14 (54) |
| Hispanic (%) | 9 (21) | 2 (5) | 4 (19) | 2 (8) |
| Other (%) | 0 | 3 (8) | 0 | 1 (4) |
| Route of HIV infection | ||||
| Intravenous drug use (%) | 12 (29) | 17 (45) | 8 (38) | 9 (35) |
| Heterosexual contact (%) | 28 (67) | 18 (47) | 12 (57) | 14 (54) |
| Other/unknown (%) | 2 (5) | 3 (8) | 1 (5) | 3 (11) |
| Previous HAART (%)† | 11 (26) | 7 (18) | 5 (24) | 8 (31) |
| Log10 HIV RNA* | 4.7 (2.6, 5.8) | 4.9 (2.7, 5.9) | 5.0 (3.8, 5.9) | 4.7 (2.7, 5.8) |
| CD4 cell count per μL* | 19 (2, 156) | 12 (2, 357) | 14 (2, 84) | 6 (1, 303) |
Of 110 female subjects transfused during the VATS, 80 had evaluable samples after their first (T1) transfusions, and 47 had evaluable samples after their second (T2) transfusions.
Median values are followed by 10th and 90th percentiles in parentheses.
Highly active antiretroviral therapy exposure before transfusion.
LR, leukoreduced study arm; NLR, nonleukoreduced study arm.